Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00051025 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00051025: Completed Phase 2 study, sponsored by Eisai.
NCT00051025 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00051025, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to look at the safety and effectiveness of ONTAK in previously treated patients with NHL.
Primary Outcome
Complete response: achievement of a complete regression for \>4 weeks of all palpable and x-ray demonstrable disease and bone marrow disease. Partial response: response to therapy with a 75% reduction in the greatest diameters of the measurable lesions for \>4 weeks and had indeterminate bone marrow biopsy
Interventions
- DRUG ONTAK
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2000-05 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
What the finished NCT00051025 record still lists
NCT00051025 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which ONTAK is the first listed.
NCT00051025 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00051025 about?
NCT00051025 is a clinical study titled "Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)". The purpose of this study is to look at the safety and effectiveness of ONTAK in previously treated patients with NHL.
What is the current status of trial NCT00051025?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2000-05. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00051025?
The interventions under investigation include: ONTAK (DRUG).
Who is sponsoring clinical trial NCT00051025?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00051025's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia